Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge
Pharmaceuticals · 16.01.2026 · 19 (1) · 162
DOI: 10.3390/ph19010162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 16.01.2026. Verfasst von Anna Gallina und 5 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS ISMETT, 90127 Palermo, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Italian Ministry of Health, Rome, Italy (Ricerca Corrente)., Italian Ministry of Health, Rome, Italy.
Abstract (Originalsprache)
Bacteriophage (phage) therapy, including monophage preparations, phage cocktails, engineered phages, and phage-derived enzymes, has re-emerged as a potential option for difficult-to-treat and biofilm-associated infections in the context of rising antimicrobial resistance. Recent scientific and regulatory developments, such as the 2024 World Health Organization Bacterial Priority Pathogens List and the introduction of the European Pharmacopoeia general chapter 5.31 on phage therapy medicinal products, highlight the growing interest in establishing quality, safety, and governance standards for clinical implementation. This narrative review provides an overview of current clinical applications of phage therapy, drawing on published case reports, case series, early-phase clinical studies, and regulatory experiences across different healthcare settings. Clinical use has been reported in respiratory, urinary tract, musculoskeletal, cardiovascular, and device-associated infections, particularly in cases involving multidrug-resistant pathogens, often in combination with antibiotics. At the same time, the biological characteristics of phages, such as strain specificity, adaptive composition of phage cocktails, and the need for individualized formulations, pose significant regulatory and translational challenges. Access to phage therapy currently relies on heterogeneous regulatory mechanisms, including compassionate use programmes, magistral preparations, named-patient pathways, and other national frameworks. Overall, phage therapy represents a promising strategy for selected infections, but its broader clinical adoption will depend on harmonized regulatory approaches, robust quality standards, and the generation of stronger clinical evidence to support safe and scalable use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS ISMETT, 90127 Palermo, Italy.
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy.
- UPMC Italy, 90133 Palermo, Italy.
ORCID-Profile: Matteo Gallina, Andrea Cona, Alessio Provenzani
Förderung
- This work was supported by the Italian Ministry of Health, Rome, Italy (Ricerca Corrente).
- Italian Ministry of Health, Rome, Italy
Zitieren
APA
Gallina, A., Gallina, M., Cona, A., Vitulo, P., Mularoni, A., & Provenzani, A. (2026). Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge. Pharmaceuticals, 19(1), 162. https://doi.org/10.3390/ph19010162
Vancouver
Gallina A, Gallina M, Cona A, Vitulo P, Mularoni A, Provenzani A. Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge. Pharmaceuticals. 2026;19(1):162. doi:10.3390/ph19010162
BibTeX
@article{Gallina2026,
author = {Gallina, Anna and Gallina, Matteo and Cona, Andrea and Vitulo, Patrizio and Mularoni, Alessandra and Provenzani, Alessio},
title = {Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {1},
pages = {162},
doi = {10.3390/ph19010162}
}
EUVIMED